JEITO’S TEAM

Dr Rafaèle Tordjman, MD PhD, has been an investor in life sciences for almost 20 years. She joined Sofinnova Partners, a Paris-based venture capital firm, in 2001, as an analyst. She became co-leader and partner with €1.5 billion in assets under management, which she held until 2017.

Rafaèle has invested in and served on the boards of a number of life science companies, including DBV Technologies [DBV], Ascendis [ASND], Lysogene [LYS], MedDay, Enyo Pharma, Nucana Biomed [NCNA], Flexion Therapeutics [FLXN] and Preglem, before the company was sold to Gedeon Richter.

Prior to this, Dr. Tordjman worked as a physician and researcher in haemato-oncology. After five years working at the Paris University Hospitals as a medical doctor specialising in internal medicine and clinical hematology, she presented her doctoral thesis on Haematopoiesis and Angiogenesis, which she obtained in 2000. She then completed her post-doctoral work in immunology at INSERM, Cochin Hospital, and published in Nature Immunology among others. In 2002, she also completed a management training course at INSEAD.

In 2018, Rafaèle founded Jeito Capital, an independent investment company dedicated to biopharma/biotech to establish a model of continuous financing and to invest in the next generation of leaders in medical innovation. Jeito I raised €534 million ($630 million) in September 2021, becoming the largest independent European fund in Life Sciences.

To engage more women in the life sciences industry, in 2010 she founded the association W.I.T.H. (Women Innovating Together in Healthcare) that now has a global membership of 500 women representing the full chain of medical innovation. Please visit their website at https://with-association.com/.

In September 2020, she was awarded  Chevalier de la Légion d’Honneur, France’s highest distinction, for her achievements. Prior to joining Sofinnova Partners, Rafaèle worked as a physician and researcher in haemato-oncology.

In July 2021, Dr. Tordjman was appointed by Agnès Pannier-Runacher, Minister Delegate for Industry and Franck Riester, Minister Delegate for Foreign Trade and Economic Attractiveness, under the high patronage of President Emmanuel Macron to promote the French Biopharma and healthcare innovation ecosystem among leading international players.

Dr. Tordjman has also been nominated in the 2023 Forbes “50 Over 50” selection across Europe, Middle East And Africa, spotlighting successful women who are reaching new heights in their industries.

Sabine Dandiguian is Managing Partner at Jeito Capital and has over 30 years of experience in the pharmaceutical and medical devices industry.

Sabine has in-depth operational and strategic capabilities, particularly in market access, innovative “business models” and management.

Prior to Jeito, she spent 20 years at Johnson & Johnson, in operational positions of increasing responsibility, notably at Janssen (Johnson & Johnson’s pharmaceutical arm) as President France in 2005, then Managing Director  of European emerging countries, in charge of  Russia, Turkey, the Middle East and Africa. Three years later, she was promoted to Company Group Chairman, President Europe of Johnson & Johnson’s medical business, managing  $3.5bn of turnover  and an international team of 4,500 people.

Sabine has been recognized as Chevalier de l’Ordre du Mérite and Chevalier de la Légion d’Honneur.

She has been a member of W.I.T.H. (Women Innovating Together in Healthcare) since its creation.

Sabine graduated in Finance from ESCP Business School (Grande Ecole).

Ksenija Pavletic is a General Partner and Chief Commercial Officer (“CCO”) at Jeito Capital with over 25 years’ experience in pharma & biotech. She is an expert in both investment strategies and healthcare companies scaleups with a successful track record in fund raising, M&A, company & teams build ups, commercial organization build ups, product launches, market access.

As part of the Jeito founding team, Ksenija contributed to Jeito’s development as Chief Commercial Officer before being promoted Partner Investor in November 2023.

Prior to joining Jeito, she was CEO of Swiss-based, reproductive health pharma company PregLem SA where she led the company’s rapid expansion including its successful exit for CHF445 million three years after the inception.

Prior to PregLem, Ksenija worked for eleven years with Serono (then Merck Serono) in various regional and global business, sales and marketing positions.

Ksenija holds a M.Sc. in Biotechnology from University of Zagreb and an MBA from American Graduate School of Business.

Ksenija is also a member of W.I.T.H. (Women Innovating Together in Healthcare).

Annette works on Pharma M&A Strategy at Jeito Capital

Annette is part of the Jeito’s founding team and has more than 30 years of international Pharma experience in US & Europe with proven executive leadership in strategy, global Business Development and international M&A.

She also brings over a decade of life sciences venture capital experience, with a focus on biotech investments, Board leadership, and successful exits.

Annette worked for 30 years with GSK, where she led the Worldwide Transactions and Alliance management function for the latter 10 years. She executed many innovative deals ranging from early drug discovery partnerships to global commercial alliances and led over 30, multibillion dollar deals.

Annette holds a BSc degree in Pharmacology from Bath University. She is also a member of W.I.T.H. (Women Innovating Together in Healthcare).

Karin brings over 30 years of experience in global regulatory affairs.

Karin spent nearly a decade as Global Head of Regulatory Affairs at Janssen, the pharmaceutical division of Johnson & Johnson, one of the top pharmaceutical companies worldwide, holding senior leadership roles across global, regional, and operational regulatory functions.

Throughout his professional journey over more than 35 years, Pascal has remained dedicated to transforming the lives of patients with serious medical conditions through his passion for pioneering science, collaborative leadership, and a steadfast commitment to excellence.

Pascal was CEO of Atara Biotherapeutics (Nasdaq: ATRA) in California from 2019 to 2024, where he led the company’s transformation into a leader in cell therapy, obtaining in 2022 the first-ever regulatory approval for an allogeneic T-cell therapy, EBVALLO® (tabelecleucel). He was Chairman of the Board of the company from September 2024 to September 2025.

Before joining Atara, Pascal was Senior Vice President and Global Head of Cell & Gene at Novartis Oncology, where he led the development, regulatory approval and global launch of KYMRIAH® (tisagenlecleucel), the first CAR-T therapy approved in the US. He also served previously as Global Head of Strategy and Business Development for Oncology and was a member of the Novartis Oncology Executive Committee. Earlier in his career, he held various roles across research, marketing, general management of subsidiaries and geographic areas, strategy and business development at Servier and GSK.

He is also an Independent Director on the Boards of Ipsen (Euronext: IPN, ADR: IPSEY), Medincell (Euronext Paris: MEDCL), RoslinCT, and CDR-Life[1], as well as representing Jeito on the Boards of CatalYm[1] and XyloCor Therapeutics[1].

He previously served on the Boards of Atara Biotherapeutics (Nasdaq: ATRA), Genoptix, Navigate Biopharma Services, and Cogen Therapeutics.

Pascal holds a Doctorate in Veterinary Medicine from Paul Sabatier University (Toulouse, France), a DESS in Management from IAE Toulouse, and an MBA from INSEAD.

[1] CDR-Life, CatalYm, and XyloCor Therapeutics are Jeito portfolio companies.

Claudio is part of Jeito Capital’s founding team and has over 25 years of experience in biomedical sciences in Europe, US & Brazil, including 7 years in venture capital industry in Europe, and positions in Scientific & Strategic Boards. Claudio brings a strong track record spanning from R&D, venture investment, and academic leadership.

Previously, Claudio was Professor of Biochemistry and Head of translational research unit, and Head of Department at the University of Sao Paulo Medical School, having published ~100 articles, presented lectures worldwide, and was part of editorial board of scientific journals.

Claudio holds a PhD in Molecular Biology and Molecular Pharmacology, completed through joint research conducted at the Federal University of São Paulo (Brazil) and the University of Copenhagen (Denmark). He also holds a Habilitation Degree (Privatdozent) in Structural Biochemistry and was a visiting fellow at Collège de France and Institute Cochin (France).

Evaldo Bifulco is Head of Sustainability, Compliance & Risk (RCCI) at Jeito.

Prior to joining Jeito, Evaldo worked at ODDO BHF Asset Management SAS and ODDO BHF Private Equity SAS first as a Compliance Officer and quickly became Head of Compliance Department (RCCI) of ODDO BHF Private Equity.

He was previously Financial Risk Consultant at EY working on compliance regulatory projects, risk & compliance due diligences and internal audits for Private Equity firms and Asset Managers.

Evaldo began his career as a Compliance Officer at Société Générale Gestion (Amundi Group).

Evaldo holds a Master 1 in Finance and a Master 2 in Banking Risk Management and Compliance from the Université Paris 1 – Panthéon Sorbonne. 

Maya joined Jeito Capital as a Junior Analyst in January 2020, became an Analyst in December 2020, an Associate in December 2021, a Senior Associate in January 2024, and progressed to Principal in October 2025.

In parallel to her work at Jeito Capital, Maya launched a NGO in the healthcare sector to bring drugs to patients in high unmet need abroad.

Prior to joining Jeito Capital, Maya held operational roles in Biotech working closely with management in the first months/years of launch on different subjects such as financing and competitive intelligence, and technology differentiation.

Maya holds complementary degrees in both the scientific field as Doctor in Pharmacy from Université Paris Descartes and a Master’s degree in chemistry, and the business field with a Master in Management degree from ESSEC Business School (Parcours Grande Ecole).

Julien Elric is a Senior Principal at Jeito Capital, bringing strong experience in deal sourcing, portfolio support, and healthcare investment.

He joined Jeito in September 2021 as an Associate (2021) before being promoted Senior Associate in 2023 and Principal in early 2024. Within Jeito’s investment team, Julien has contributed to financing efforts and clinical development strategies across the portfolio.

Before joining Jeito, Julien led the startup incubator iPEPS at the Paris Brain Institute, where he helped establish it as a key hub for life sciences innovation in France. He supported early-stage biotechs and medtechs in their growth (fund raising, partnerships) and advised major pharmaceutical companies (Pfizer, Janssen, Astra Zeneca, etc.) on corporate–startup collaborations. Earlier in his career, he was responsible for business development and industrial partnerships at Institut Curie.

Julien holds a PhD in Cell Biology from Institut Pasteur and is a graduate of INSEAD Business School.

Chloé Morlaàs is Investor Relations & Chief of Staff to the CEO at Jeito.

Before joining Jeito, Chloé worked in a healthcare consulting firm advising pharmaceutical companies on specific topics (drug brand plan, mapping of patients’ associations for strategic partnership). She then gained experience in a HealthTech association where she learnt about the key challenges and opportunities of this ecosystem and contributed to making recommendations for the government.

Chloé holds a Master of Science in Management from ESSEC Business School (“Grande Ecole Program”) after preparatory classes and a Master of Philosophy in Science from the London School of Economics (LSE).

Prior to joining Jeito, Elsa worked in the healthtech sector for seven years in support of biopharmaceuticals and medtech companies. She worked at EY, as a financial consultant, primarily advising biopharmaceutical and medtech companies on IPOs on Euronext and Nasdaq as well as IFRS implementation.

Prior to joining EY, Elsa was an M&A Manager at Pierre Fabre, one of the first French private pharmaceutical and dermo-cosmetic companies, where she coordinated buyer and seller due diligences, participated in the identification of new targets and in negotiations related to the creation of a joint-venture and the sale of a manufacturing plant.

Elsa began her career in 2014 as financial auditor at EY, specialized in the pharmaceutical and Healthtech industries.

Elsa holds a Master of Science in Corporate Finance and a Master in Management from EDHEC Business School.

Mehdi Ainouche, PharmD, is Partner at Jeito Capital.

With over a decade of experience in life sciences investment, he is involved across the full investment cycle – from deal sourcing and due diligence to closing and exit.

Mehdi joined Jeito in 2020 as Principal before being promoted to Senior Principal in 2024 and Partner in 2025. Since 2020, He has supported several investments and portfolio companies, particularly in ophthalmology, oncology, cardiometabolic and neuromuscular diseases, as well as fibrosis.

Before joining Jeito, Mehdi was an Associate within the healthcare venture team of Turenne Capital, a French investment group with over €2Bn under management, where he worked on numerous biotech and medtech investments.

He holds a Doctorate in Pharmacy from the University of Rennes 1 and a Master’s in Business from ESCP Europe.

As Partner, he will contribute further to building Jeito portfolio diversification and performance.

Charlotte joined Jeito in 2022 as an Associate Counsel, and progressed to Senior Legal Counsel in October 2024.

Prior to joining Jeito, Charlotte worked from 2017 to 2022 at Weil Gotshal & Manges (Paris) LLP as an attorney in the private equity team, where she advised private equity funds and corporates on LBO, M&A and growth deals.

Prior to that, she interned at several tier one international law firms in Paris, mainly in the private equity practice.

Charlotte is a member of the Paris Bar and a graduate of the London School of Economics (LLM degree in Corporate law) and Sciences Po Paris (Master’s degree in Economic law and B.A.)